(24 days)
Not Found
No
The document describes standard image viewing, processing, and storage software without mentioning AI or ML capabilities.
No.
The device is described as a software solution for viewing, communication, and storage of medical images, and supports interpretation of examinations, but it does not directly provide therapy or treatment.
Yes
Explanation: The device is described as supporting "interpretation of examinations" and helping "an authorized user in diagnosis and treatment planning," which are functions consistent with a diagnostic device.
Yes
The device description explicitly states "syngo®.via protoNeo version VA10A is a software only medical device." and clarifies that the hardware it runs on is not considered a medical device and is outside the scope of the 510(k).
Based on the provided text, this device is not an In Vitro Diagnostic (IVD).
Here's why:
- Intended Use: The intended use clearly states the software is for "viewing, communication, and storage of medical images" and supports "interpretation of examinations within healthcare institutions." This focuses on the processing and display of images acquired from imaging modalities like CT and MR, which are in vivo (within the living body) diagnostic methods.
- Device Description: The description reinforces this by stating the system "receives, stores and distributes images from digital image acquisition devices such as computer tomography and magnetic resonance scanners." It also mentions tools to "review, edit, and manipulate image data, as well as generate quantitative and qualitative data to support an authorized user in diagnosis and treatment planning." This is consistent with image processing and analysis for in vivo imaging.
- Lack of Mention of In Vitro Samples: There is no mention of analyzing biological samples (blood, tissue, urine, etc.) or performing tests on samples outside of the body, which is the defining characteristic of an IVD.
Therefore, syngo via protoNeo is a medical image processing and management software, not an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
syngo®.via protoNeo is a software solution intended to be used for viewing, communication, and storage of medical images.
It can be used as a stand-alone device or together with a variety of cleared and unmodified syngo based software options.
syngo via protoNeo supports interpretation of examinations within healthcare institutions, for example, in Radiology, Nuclear Medicine and Cardiology environments.
The system is not intended for the displaying of digital mammography images for diagnosis in the U.S.
Product codes (comma separated list FDA assigned to the subject device)
LLZ
Device Description
This premarket submission addresses the Siemens syngo®.via protoNeo Version VA10A Picture Archiving and Communication System.
syngo®.via protoNeo, version VA10A, is a medical software system that provides tools and features to cover the radiological tasks of reading images. The system receives, stores and distributes images from digital image acquisition devices such as computer tomography and magnetic resonance scanners. The system has workplaces which can be used to review, edit, and manipulate imaqe data, as well as generate quantitative and qualitative data to support an authorized user in diagnosis and treatment planning.
syngo®.via protoNeo version VA10A is a software only medical device. It defines recommended configurations for the hardware to run on. The hardware itself is not seen as a medical device and is not within the scope of this 510(k) submission.
syngo®.via protoNeo is based on a client-server architecture. The server processes and renders the data from the connected modalities. The server provides central services including image processing and temporary storage while incorporating the local database. The client provides the user interface for interactive image viewing and processing and can be installed and stored on each workplace that has a network connection to the server.
Since the majority of the data processing is performed by the server, the client can be installed on standard off-the-shelf computers with a variety of monitor types. The quality of displayed images highly depends on the quality and settings of monitors, graphics cards, and graphics drivers. It is the customer's responsibility that client monitors are compatible with graphics cards and graphics drivers. It is also the customer's responsibility to use suitable monitors for diagnostic purposes.
In the United States, monitors (displays) should not be used for diagnosis, unless the monitor (display) has specifically received 510(k) clearance for this purpose.
syngo®.via protoNeo and its predicate device have the same fundamental technical characteristics.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
CT and MR
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
healthcare institutions, for example, in Radiology, Nuclear Medicine and Cardiology environments.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Non-clinical testing was conducted for the device syngo.via protoNeo during product development. The modifications described in this Premarket Notification were supported with verification and validation testing.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 892.2050 Medical image management and processing system.
(a)
Identification. A medical image management and processing system is a device that provides one or more capabilities relating to the review and digital processing of medical images for the purposes of interpretation by a trained practitioner of disease detection, diagnosis, or patient management. The software components may provide advanced or complex image processing functions for image manipulation, enhancement, or quantification that are intended for use in the interpretation and analysis of medical images. Advanced image manipulation functions may include image segmentation, multimodality image registration, or 3D visualization. Complex quantitative functions may include semi-automated measurements or time-series measurements.(b)
Classification. Class II (special controls; voluntary standards—Digital Imaging and Communications in Medicine (DICOM) Std., Joint Photographic Experts Group (JPEG) Std., Society of Motion Picture and Television Engineers (SMPTE) Test Pattern).
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized caduceus symbol, which is a staff with two snakes entwined around it, superimposed over three human profiles facing right. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the symbol.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
July 11, 2016
Siemens Healthcare GmbH % Mr. Georg Bauer Responsible Third Party Official 510(k) TPR Deputy Program Manager TÜV SÜD America, Inc. 1775 old highway 8 NW, Suite 104 NEW BRIGHTON MN 55112-1891
Re: K161685
Trade/Device Name: syngo®.via protoNeo (Version VA10A) Regulation Number: 21 CFR 892.2050 Regulation Name: Picture archiving and communications system Regulatory Class: II Product Code: LLZ Dated: June 14, 2016 Received: June 17, 2016
Dear Mr. Bauer:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
1
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Michael D.'Hara
For
Robert Ochs, Ph.D. Director Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K161685
Device Name syngo®.via protoNeo (Version VA10A)
Indications for Use (Describe)
syngo via protoNeo is a software solution intended to be used for viewing, communication, and storage of medical images.
It can be used as a stand-alone device or together with a variety of cleared and unmodified syngo based software options.
syngo via protoNeo supports interpretation of examinations within healthcare institutions, for example, in Radiology, Nuclear Medicine and Cardiology environments.
The system is not intended for the displaying of digital mammography images for diagnosis in the U.S.
| Type of Use (Select one or both, as applicable) |
|---|
| ------------------------------------------------- |
| X Prescription Use (Part 21 CER 801 Subpart D) | ☐ Over-The-Counter Use (21 CER 801 Subpart C) |
|---|---|
| ------------------------------------------------------------------------------------------------ | ----------------------------------------------------------------------------------------------- |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW!
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Image /page/3/Picture/0 description: The image shows the word "SIEMENS" in a bold, sans-serif font. The color of the text is a bright teal. The letters are evenly spaced and the word is horizontally oriented. The background is plain white.
510(k) Summary
syngo®.via protoNeo (Version VA10A)
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR §807.92.
Date prepared: June 1, 2016
1. Submitter
Siemens Healthcare GmbH Henkestrasse 127 D-91052 Erlangen Germany
Establishment Registration Number 3002808157
2. Contact Person
Ms. Lauren Bentley Regulatory Affairs Manager Siemens Healthcare GmbH 40 Liberty Boulevard Mailcode: 65-3 Malvern, PA 19355 USA Email: lauren.bentley@siemens.com Telephone: +1 (610) 448 - 6104 Fax: +1 (610) 448 – 6557
3. Device Name and Classification
| Trade Name: | syngo®.via protoNeo (Version VA10A) |
|---|---|
| Classification Name: | Picture Archiving and Communication System |
| Classification Panel: | Radiology |
| CFR Section: | 21 CFR §892.2050 |
| Device Class: | Class II |
| Product Code: | LLZ |
4. Legally Marketed Predicate Device
| Trade Name: | syngo.via |
|---|---|
| 510(k) Clearance: | K150843 |
| Clearance Date: | April 24, 2015 |
4
| Classification Name: | Picture Archiving and Communication System |
|---|---|
| Classification Panel: | Radiology |
| CFR Section: | 21 CFR §892.2050 |
| Device Class: | Class II |
| Product Code: | LLZ |
| Recall Information: | This predicate device has not been the subject of any |
| design related recalls. |
5. Device Description
This premarket submission addresses the Siemens syngo®.via protoNeo Version VA10A Picture Archiving and Communication System.
syngo®.via protoNeo, version VA10A, is a medical software system that provides tools and features to cover the radiological tasks of reading images. The system receives, stores and distributes images from digital image acquisition devices such as computer tomography and magnetic resonance scanners. The system has workplaces which can be used to review, edit, and manipulate imaqe data, as well as generate quantitative and qualitative data to support an authorized user in diagnosis and treatment planning.
syngo®.via protoNeo version VA10A is a software only medical device. It defines recommended configurations for the hardware to run on. The hardware itself is not seen as a medical device and is not within the scope of this 510(k) submission.
syngo®.via protoNeo is based on a client-server architecture. The server processes and renders the data from the connected modalities. The server provides central services including image processing and temporary storage while incorporating the local database. The client provides the user interface for interactive image viewing and processing and can be installed and stored on each workplace that has a network connection to the server.
Since the majority of the data processing is performed by the server, the client can be installed on standard off-the-shelf computers with a variety of monitor types. The quality of displayed images highly depends on the quality and settings of monitors, graphics cards, and graphics drivers. It is the customer's responsibility that client monitors are compatible with graphics cards and graphics drivers. It is also the customer's responsibility to use suitable monitors for diagnostic purposes.
In the United States, monitors (displays) should not be used for diagnosis, unless the monitor (display) has specifically received 510(k) clearance for this purpose.
syngo®.via protoNeo and its predicate device have the same fundamental technical characteristics.
5
6. Intended Use
syngo.via protoNeo is a software solution intended to be used for viewing, manipulation, communication, and storage of medical images.
It can be used as a stand-alone device or together with a variety of cleared and unmodified synqo based software options.
syngo.via protoNeo supports interpretation and evaluation of examinations within healthcare institutions, for example, in Radiology, Nuclear Medicine and Cardiology environments.
The system is not intended for the displaying of digital mammography images for diagnosis in the U.S
7. Summary of Differences Between the Subject Device and the Predicate Device
The differences between the subject device described in this premarket notification and the predicate device are summarized in the following comparison table:
| | Subject Device
syngo.via protoNeo VA10A | Predicate Device
syngo.via VB10A |
|--------------------------|------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Manufacturer | Siemens Healthcare GmbH | Siemens AG |
| Software
Architecture | Client-server architecture with
enhanced business logic on the
client side. | Client-server architecture |
| Network Bandwidth | Minimum:
3 Mbits/second, 50 ms round-trip | Minimum:
1 Gbit ethernet3 |
| Operating System | Client:
Microsoft Windows 7
Server:
Microsoft Windows
Server 2012 R2 | Client:
Microsoft Windows 7 SP1 or
Microsoft Windows 8.1
Server:
Microsoft Windows Server
2008 R2, or Microsoft Windows
Server 2012 R2 |
| Patient Browser | Yes, with simplified search
functionality and clearer
structure of search results | Yes |
| Ranges | Yes, with a simplified ranges
control panel. | Yes |
| Image Display | CT and MR | DICOM Ultrasound, XA, CT,
MR, DX, DR and Nuclear
Medicine, including PET. |
| Imaging Algorithms | - Multiplanar reconstruction
(MPR)
- Maximum Intensity Projection
(MIP) - Volume Rendering Technique | - Multiplanar reconstruction
(MPR) - Maximum Intensity Projection
(MIP) - Volume Rendering Technique |
6
| | (VRT) with edge and surface
enhancements and control
over rendering parameters
- MPR Curved (Curved Planar
Reformat, CPR) - Region growing | (VRT) with edge and surface
enhancements and control over
rendering parameters - MPR Curved
- Region growing |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|
| Export Data Sets via
Network Means | Export to other DICOM nodes. | Export to Windows file system, or
other DICOM nodes. |
8. Non-Clinical Performance Testing
Non-clinical testing was conducted for the device syngo.via protoNeo during product development. The modifications described in this Premarket Notification were supported with verification and validation testing.
Siemens claims conformance to the following standards:
- NEMA PS3 Digital Imaging and Communications in Medicine (DICOM) ●
- ISO 14971:2007 ●
- ANSI/AAMI ES 60601-1, A1, clauses 14.11 and 14.13 .
- IEC 62304: 2006
- IEC 62366-1:2015
- IEC 10918-1:1994 + Technical Corrigendum 1:2005 ●
- IEC 15444-1:2005 + Technical Corrigendum 1:2007
Software Verification and Validation
In accordance with the FDA's Guidance Document "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices" issued on May 11, 2005, documentation is included within this submission for software of a Moderate Level of Concern. Non-clinical Testing was conducted during product development. Evidence provided within this submission demonstrates conformance with special controls for medical devices containing software.
Cybersecurity considerations related to syngo.via protoNeo are included within this submission. Siemens conforms to cybersecurity requirements by implementing a means to prevent unauthorized access, modification, misuse, denial of use or unauthorized use of information stored, accessed or transferred from a medical device to an external recipient.
A risk analysis, in compliance with ISO 14971:2007, for syngo.via protoNeo was conducted and mitigation controls were implemented for identified hazards. Verification and validation testing confirms that all software specifications have been implemented met the defined acceptance criteria. Further, documentation is provided to support the claim of substantial equivalence.
7
9. Safety and Effectiveness Information
Device labeling contains instructions for use and any necessary cautions and warnings to provide for safe and effective use of this device. Risk management was implemented throughout the development process to control potential hazards.
The device does not come into contact with the patient and is only used by trained professionals. The output of the device is evaluated by clinicians, providing for sufficient review to identify and intervene in the event of a malfunction.
Siemens believes that syngo.via protoNeo version VA10A is safe and effective as the identified predicate device and does not introduce new safety and effectiveness concerns.
10. Conclusion as to Substantial Equivalence
The comparison of intended use, technological characteristics, performance specifications, device hazards as well as verification and validation results demonstrate that syngo.via protoNeo is safe, effective and performs as well as the predicate device.
In summary. Siemens is of the opinion that syngo.via protoNeo version VA10A does not introduce any new significant potential safety risks and is substantially equivalent to the predicate device.